This study focuses on patients with advanced cancer or metastatic tumors that have specific molecular changes. The study will test several anti-cancer medications including ribociclib, siremadlin (HDM201), trametinib, dabrafenib, alectinib, regorafenib, cabozantinib, and avapritinib. These medications are designed to target specific changes found in cancer cells.
The purpose of this research is to evaluate how well these medications work when matched to specific molecular changes in a patient’s tumor. Each medication will be used to treat cancers that have particular genetic alterations that the drug is designed to target. For example, some patients will receive treatment with trametinib and dabrafenib if their tumor has a specific type of BRAF mutation.
During the study, participants will receive their assigned medication and will be monitored for how their cancer responds to treatment. The medications are taken by mouth daily, and patients will be followed for up to 60 months to assess how well the treatment works. The study will measure if the cancer stops growing or shrinks, and how long any benefits from the treatment last.



France